Immunovant, Inc. IMVT Income Statement
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| $456.66M+11.9% | $408.02M+1.1% | $403.62M+4.4% | $386.64M+7.1% | $360.92M+8.3% | ||
| $76.24M-3.7% | $79.15M-5.2% | $83.49M-1.1% | $84.45M+9.3% | $77.24M+7.4% | ||
| $532.9M+9.4% | $487.17M0.0% | $487.11M+3.4% | $471.09M+7.5% | $438.15M+8.1% | ||
| $25.33M+4.8% | $24.16M+3.2% | $23.42M-2.0% | $23.89M-3.4% | $24.73M-5.7% | ||
| $2.18M-11.1% | $2.45M+96.3% | $1.25M-23.3% | $1.63M+247% | $470K+115% | ||
| -$505.39M-9.7% | -$460.56M+0.4% | -$462.44M-3.8% | -$445.58M-7.9% | -$412.95M-8.1% | ||
| —— | $3.64M+62.4% | $2.24M+29.9% | $1.73M+93.9% | $890K+65.1% | ||
| -$505.61M-8.9% | -$464.2M+0.1% | -$464.69M-3.9% | -$447.3M-8.1% | -$413.84M-8.1% | ||
| -$2.78-3.7% | -$2.68+5.3% | -$2.83+0.4% | -$2.84-4.0% | -$2.73-4.2% | ||
| -$479.65M-10.0% | -$435.97M+0.6% | -$438.61M-4.1% | -$421.29M-8.6% | -$387.84M-9.1% | ||
| -$480.06M-10.0% | -$436.4M+0.6% | -$439.03M-4.1% | -$421.69M-8.6% | -$388.22M-9.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Immunovant, Inc. profitable?
- Immunovant, Inc. is not currently profitable: it reported a net loss of $505.6M over the trailing twelve months.
- What is Immunovant, Inc.'s earnings per share?
- Immunovant, Inc.'s diluted EPS over the trailing twelve months is $-2.78.
- Where does Immunovant, Inc.'s income statement data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.